In addition, because systemic loss of ELOVL2 enzymatic activity resulted in downregulation of B cell genes that are also associated with lymphoproliferative neoplasms, this study sheds light on an intriguing metabolic pathway that could be leveraged in future studies as a novel therapeutic modality (potentially by down-modulating ELOVL2 expression or activity) to target blood cancers or other age-related conditions involving the B cell lineage. Here, ELOVL2 is linked to hematopoietic and lymphoid system neoplasm.